CERE - CEREVEL INVESTOR REMINDER: Think $45 Per Share is Too Low for Cerevel (Nasdaq:CERE)? Contact BFA Law about Continuing Investigation into the Offer | Benzinga

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation.

Claim Details:

On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected ...

CERE)? Contact BFA Law about Continuing Investigation into the Offer>Full story available on Benzinga.com